Cargando…
Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan
BACKGROUND: The investigational medicinal product GKT137831 is a selective inhibitor of NOX 1 and 4 isoforms of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes, which has the potential to ameliorate diabetic kidney disease. An investigator-initiated, double-blind, r...
Autores principales: | De Livera, Alysha M., Reutens, Anne, Cooper, Mark, Thomas, Merlin, Jandeleit-Dahm, Karin, Shaw, Jonathan E., Salim, Agus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268311/ https://www.ncbi.nlm.nih.gov/pubmed/32493401 http://dx.doi.org/10.1186/s13063-020-04404-0 |
Ejemplares similares
-
Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina
por: Deliyanti, Devy, et al.
Publicado: (2015) -
Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells
por: Demircan, Muhammed Burak, et al.
Publicado: (2022) -
Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/MAPK Pathway
por: Zheng, Hui, et al.
Publicado: (2022) -
Inhibition of the ROS-EGFR Pathway Mediates the Protective Action of Nox1/4 Inhibitor GKT137831 against Hypertensive Cardiac Hypertrophy via Suppressing Cardiac Inflammation and Activation of Akt and ERK1/2
por: Zeng, Si-yu, et al.
Publicado: (2020) -
Coping with Persistent Pain, Effectiveness Research into Self-management (COPERS): statistical analysis plan for a randomised controlled trial
por: Kahan, Brennan C, et al.
Publicado: (2014)